Trying Time for GVK Bio as WHO Too Opens Probe

Published: 08th December 2014 06:01 AM  |   Last Updated: 08th December 2014 06:01 AM   |  A+A-

HYDERABAD: Trouble seems to be compounding for city-based GVK Biosciences Pvt Ltd with the World Health Organization (WHO) too initiating an investigation to determine the authenticity of GVK Bio’s Bio-Equivalence (BE) studies.

WHO, which manages the UN’s Pre-Qualification Medicines Programme, joins the European health regulatory bodies, including the European Medical Agency (EMA) that’s inspecting all the BE trials the company had conducted between 2008 and 2014.

The WHO Pre-qualification Team has contacted GVK Bio and the respective holder of pre-qualification to obtain further information, including the results of a thorough risk-assessment, regarding the extent to which deficiencies identified by the French Medical Agency, ANSM, apply to the pre-qualified products, WHO said in a note dated August 7. It added that WHO will gather and analyse information obtained from GVK and the pre-qualification holder, and will inform regulators and other parties concerned accordingly.

It may be noted that WHO has pre-qualified — WHO pre-qualification allows companies to provide medicines for national and international immunisation programmes — two medicinal products for which assessment of product safety and efficacy was supported by the results of clinical BE trials performed by GVK Bio. It is unclear if the WHO probe is limited to these two products or GVK’s entire clinical research operations.

According to WHO, the investigation was initiated following the French Medical agency ANSM’s inspection, and with the Co-ordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh of the EMA) requesting that, within Europe, all applicants seeking marketing authorization for any product for which GVK Bio had conducted a BE trial since July 2008, and all holders of a marketing authorization for any product for which GVK Bio has conducted clinical studies since July 2008, provide information on the significance of these studies.

When contacted, GVK Bio said it had provided the data WHO had asked for. While the EMA had found all GVK BE studies insufficient, some EU members suspended 25 medicines that used the data.

Stay up to date on all the latest Telangana news with The New Indian Express App. Download now
(Get the news that matters from New Indian Express on WhatsApp. Click this link and hit 'Click to Subscribe'. Follow the instructions after that.)

Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp